Breast cancer (non-metastatic)
Identifieur interne : 003411 ( Ncbi/Merge ); précédent : 003410; suivant : 003412Breast cancer (non-metastatic)
Auteurs : Justin Stebbing ; Geoff Delaney ; Alistair ThompsonSource :
- BMJ Clinical Evidence [ 1752-8526 ] ; 2007.
Abstract
Breast cancer affects at least 1 in 10 women in the UK, but most present with primary operable disease, which has an 80% 5-year survival rate overall.
We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions after breast-conserving surgery for ductal carcinoma in situ? What are the effects of treatments for primary operable breast cancer? What are the effects of interventions in locally advanced breast cancer (stage IIIB)? We searched: Medline, Embase, The Cochrane Library and other important databases up to February 2006 (BMJ Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
We found 79 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
In this systematic review we present information relating to the effectiveness and safety of the following interventions: adding chemotherapy (cyclophosphamide/methotrexate/ fluorouracil and/or anthracycline and/or taxane-based regimens), or hormonal treatment to radiotherapy; adjuvant treatments (aromatase inhibitors, adjuvant anthracycline regimens, tamoxifen); axillary clearance; axillary dissection plus sentinel node dissection; axillary radiotherapy; axillary sampling; combined chemotherapy plus tamoxifen; chemotherapy plus monoclonal antibody (trastuzumab); extensive surgery; high-dose chemotherapy; hormonal treatment; less extensive mastectomy; less than whole breast radiotherapy plus breast conserving surgery; multimodal treatment; ovarian ablation; primary chemotherapy; prolonged adjuvant combination chemotherapy; radiotherapy (after breast-conserving surgery, after mastectomy, plus tamoxifen after breast-conserving surgery, to the internal mammary chain, and to the ipsilateral supraclavicular fossa, and total nodal radiotherapy); sentinel node biopsy; and standard chemotherapy regimens.
Url:
PubMed: 19450345
PubMed Central: 2943780
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 004762
- to stream Pmc, to step Curation: 004761
- to stream Pmc, to step Checkpoint: 003B80
Links to Exploration step
PMC:2943780Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Breast cancer (non-metastatic)</title><author><name sortKey="Stebbing, Justin" sort="Stebbing, Justin" uniqKey="Stebbing J" first="Justin" last="Stebbing">Justin Stebbing</name></author><author><name sortKey="Delaney, Geoff" sort="Delaney, Geoff" uniqKey="Delaney G" first="Geoff" last="Delaney">Geoff Delaney</name></author><author><name sortKey="Thompson, Alistair" sort="Thompson, Alistair" uniqKey="Thompson A" first="Alistair" last="Thompson">Alistair Thompson</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">19450345</idno><idno type="pmc">2943780</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2943780</idno><idno type="RBID">PMC:2943780</idno><date when="2007">2007</date><idno type="wicri:Area/Pmc/Corpus">004762</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">004762</idno><idno type="wicri:Area/Pmc/Curation">004761</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">004761</idno><idno type="wicri:Area/Pmc/Checkpoint">003B80</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003B80</idno><idno type="wicri:Area/Ncbi/Merge">003411</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Breast cancer (non-metastatic)</title><author><name sortKey="Stebbing, Justin" sort="Stebbing, Justin" uniqKey="Stebbing J" first="Justin" last="Stebbing">Justin Stebbing</name></author><author><name sortKey="Delaney, Geoff" sort="Delaney, Geoff" uniqKey="Delaney G" first="Geoff" last="Delaney">Geoff Delaney</name></author><author><name sortKey="Thompson, Alistair" sort="Thompson, Alistair" uniqKey="Thompson A" first="Alistair" last="Thompson">Alistair Thompson</name></author></analytic><series><title level="j">BMJ Clinical Evidence</title><idno type="eISSN">1752-8526</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Introduction</title><p>Breast cancer affects at least 1 in 10 women in the UK, but most present with primary operable disease, which has an 80% 5-year survival rate overall.</p></sec><sec><title>Methods and outcomes</title><p>We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions after breast-conserving surgery for ductal carcinoma in situ? What are the effects of treatments for primary operable breast cancer? What are the effects of interventions in locally advanced breast cancer (stage IIIB)? We searched: Medline, Embase, The Cochrane Library and other important databases up to February 2006 (BMJ Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). </p></sec><sec><title>Results</title><p>We found 79 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.</p></sec><sec><title>Conclusions</title><p>In this systematic review we present information relating to the effectiveness and safety of the following interventions: adding chemotherapy (cyclophosphamide/methotrexate/ fluorouracil and/or anthracycline and/or taxane-based regimens), or hormonal treatment to radiotherapy; adjuvant treatments (aromatase inhibitors, adjuvant anthracycline regimens, tamoxifen); axillary clearance; axillary dissection plus sentinel node dissection; axillary radiotherapy; axillary sampling; combined chemotherapy plus tamoxifen; chemotherapy plus monoclonal antibody (trastuzumab); extensive surgery; high-dose chemotherapy; hormonal treatment; less extensive mastectomy; less than whole breast radiotherapy plus breast conserving surgery; multimodal treatment; ovarian ablation; primary chemotherapy; prolonged adjuvant combination chemotherapy; radiotherapy (after breast-conserving surgery, after mastectomy, plus tamoxifen after breast-conserving surgery, to the internal mammary chain, and to the ipsilateral supraclavicular fossa, and total nodal radiotherapy); sentinel node biopsy; and standard chemotherapy regimens.</p></sec></div></front></TEI><pmc article-type="review-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Clin Evid</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Clin Evid</journal-id><journal-id journal-id-type="publisher-id">Clinical Evidence</journal-id><journal-title-group><journal-title>BMJ Clinical Evidence</journal-title></journal-title-group><issn pub-type="epub">1752-8526</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19450345</article-id><article-id pub-id-type="pmc">2943780</article-id><article-id pub-id-type="publisher-id">0102</article-id><article-categories><subj-group subj-group-type="heading"><subject>Women's Health</subject></subj-group><subj-group subj-group-type="secondary-section"><subject>Oncology</subject><subject>Care of the Elderly</subject></subj-group></article-categories><title-group><article-title>Breast cancer (non-metastatic)</article-title><alt-title alt-title-type="abridged">Primary breast cancer</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" deceased="no"><name><surname>Stebbing</surname><given-names>Justin</given-names></name><role>MRC Clinical Training Fellow</role><aff><institution>Chelsea and Westminister Hospital</institution><addr-line>London</addr-line><country>UK</country></aff></contrib><contrib contrib-type="author" equal-contrib="yes" deceased="no"><name><surname>Delaney</surname><given-names>Geoff</given-names></name><role>Director of Radiation Oncology</role><aff><institution>Cancer Therapy Centre, Liverpool Hospital</institution><addr-line>Liverpool</addr-line><country>UK</country></aff></contrib><contrib contrib-type="author" equal-contrib="yes" deceased="no"><name><surname>Thompson</surname><given-names>Alistair</given-names><prefix>Professor</prefix></name><role>Professor of Surgical Oncology</role><aff><institution>Department of Surgery and Molecular Oncology, Ninewells Hospital and Medical School, University of Dundee</institution><addr-line>Dundee</addr-line><country>UK</country></aff></contrib></contrib-group><author-notes><fn><p>JS declares that he has no competing interests. GD declares that he has no competing interests. AMT has been reimbursed by AstraZeneca, Novartis, Pfizer, and Roche for attending symposia, including a speaker fee. AMT has contributed to trials involving these companies' products, and to the ensuing publication, which forms some of the evidence referenced in this review.</p><p><italic>We would like to acknowledge previous contributors to this review, J Michael Dixon and Alan Rodger.</italic></p></fn></author-notes><pub-date pub-type="epub"><day>04</day><month>12</month><year>2007</year></pub-date><pub-date pub-type="collection"><year>2007</year></pub-date><volume>2007</volume><elocation-id>0102</elocation-id><permissions><copyright-statement>© BMJ Publishing Group Ltd, All Rights Reserved</copyright-statement><copyright-year>2007</copyright-year></permissions><self-uri xlink:type="simple" xlink:href="http://www.clinicalevidence.bmj.com/ceweb/pmc/2007/12/102/">This article is available from http://www.clinicalevidence.bmj.com/ceweb/pmc/2007/12/102/</self-uri><abstract><sec><title>Introduction</title><p>Breast cancer affects at least 1 in 10 women in the UK, but most present with primary operable disease, which has an 80% 5-year survival rate overall.</p></sec><sec><title>Methods and outcomes</title><p>We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions after breast-conserving surgery for ductal carcinoma in situ? What are the effects of treatments for primary operable breast cancer? What are the effects of interventions in locally advanced breast cancer (stage IIIB)? We searched: Medline, Embase, The Cochrane Library and other important databases up to February 2006 (BMJ Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). </p></sec><sec><title>Results</title><p>We found 79 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.</p></sec><sec><title>Conclusions</title><p>In this systematic review we present information relating to the effectiveness and safety of the following interventions: adding chemotherapy (cyclophosphamide/methotrexate/ fluorouracil and/or anthracycline and/or taxane-based regimens), or hormonal treatment to radiotherapy; adjuvant treatments (aromatase inhibitors, adjuvant anthracycline regimens, tamoxifen); axillary clearance; axillary dissection plus sentinel node dissection; axillary radiotherapy; axillary sampling; combined chemotherapy plus tamoxifen; chemotherapy plus monoclonal antibody (trastuzumab); extensive surgery; high-dose chemotherapy; hormonal treatment; less extensive mastectomy; less than whole breast radiotherapy plus breast conserving surgery; multimodal treatment; ovarian ablation; primary chemotherapy; prolonged adjuvant combination chemotherapy; radiotherapy (after breast-conserving surgery, after mastectomy, plus tamoxifen after breast-conserving surgery, to the internal mammary chain, and to the ipsilateral supraclavicular fossa, and total nodal radiotherapy); sentinel node biopsy; and standard chemotherapy regimens.</p></sec></abstract><abstract abstract-type="key-points"><title>Key Points</title><p>Breast cancer affects at least 1 in 10 women in the UK, but most present with primary operable disease, which has an 80% 5-year survival rate overall.</p><p>In women with ductal carcinoma <italic>in situ,</italic><xref ref-type="sub-article" rid="BMJ_0102_I5">radiotherapy</xref> reduces local recurrence and invasive carcinoma after breast-conserving surgery, but may not improve survival.</p><p>In women with primary operable breast cancer, survival may be increased by full surgical excision, tamoxifen, chemotherapy, radiotherapy, <xref ref-type="sub-article" rid="BMJ_0102_I4">ovarian ablation</xref> or <xref ref-type="sub-article" rid="BMJ_0102_I21">trastuzumab</xref> (in women who overexpress <italic>HER2/neu</italic> oncogene).
<list list-type="bullet"><list-item><p>Incomplete excision may increase the risk of local recurrence, but <xref ref-type="sub-article" rid="BMJ_0102_I19">less-extensive mastectomy</xref> that excises all local disease is as effective as radical mastectomy at prolonging survival, with better cosmetic results.</p></list-item><list-item><p><xref ref-type="sub-article" rid="BMJ_0102_I17">Axillary clearance</xref> (removal of all axillary lymph nodes) achieves local disease control, but has not been shown to increase survival, and can cause arm lymphoedema.</p></list-item><list-item><p><xref ref-type="sub-article" rid="BMJ_0102_I20">Sentinel lymph node biopsy</xref> or 4-node sampling may adequately stage the axilla with less morbidity compared with axillary clearance.</p></list-item><list-item><p><xref ref-type="sub-article" rid="BMJ_0102_I12">Adjuvant tamoxifen</xref> reduces the risk of recurrence and death in women with oestrogen-positive tumours, but adverse effects begin to outweigh benefit after 5 years of treatment.</p></list-item><list-item><p><xref ref-type="sub-article" rid="BMJ_0102_I16">Primary chemotherapy</xref> may facilitate successful breast-conserving surgery instead of mastectomy. <xref ref-type="sub-article" rid="BMJ_0102_I1">Adjuvant combination chemotherapy</xref> improves survival compared with no chemotherapy, with greatest benefit likely with anthracycline-based regimens at <xref ref-type="sub-article" rid="BMJ_0102_I15">standard doses</xref> for 4-6 months.</p></list-item><list-item><p>Radiotherapy decreases recurrence and mortality after <xref ref-type="sub-article" rid="BMJ_0102_I7">breast-conserving surgery</xref>. Post-<xref ref-type="sub-article" rid="BMJ_0102_I8">mastectomy</xref> radiotherapy for women who are node-positive or at high risk of recurrence decreases recurrence and mortality, but may increase mortality in node-negative women.</p></list-item><list-item><p><xref ref-type="sub-article" rid="BMJ_0102_I18">Adjuvant aromatase inhibitors</xref> improve disease-free survival compared with tamoxifen, but their effect on overall survival is unclear.<xref ref-type="sub-article" rid="BMJ_0102_I1179236786074">Adjuvant taxoid regimens</xref> may improve disease-free survival over standard anthracycline-based therapy. </p></list-item></list></p><p>In women with locally advanced breast cancer, <xref ref-type="sub-article" rid="BMJ_0102_I13">radiotherapy</xref> may be as effective as surgery or tamoxifen at increasing survival and local disease control.
<list list-type="bullet"><list-item><p>Adding <xref ref-type="sub-article" rid="BMJ_0102_I14">tamoxifen or ovarian ablation</xref> to radiotherapy increases survival compared with radiotherapy alone, but adding chemotherapy may not reduce recurrence or mortality compared with radiotherapy alone.</p></list-item><list-item><p>Chemotherapy alone, while widely used, does not improve survival in women with locally advanced breast cancer.</p></list-item></list></p></abstract><counts><table-count count="4"></table-count><ref-count count="134"></ref-count></counts></article-meta><notes notes-type="disclaimer"><sec><title>Disclaimer</title><p>The information contained in this publication is intended for medical professionals. Categories presented in Clinical Evidence indicate a judgement about the strength of the evidence available to our contributors prior to publication and the relevant importance of benefit and harms. We rely on our contributors to confirm the accuracy of the information presented and to adhere to describe accepted practices. Readers should be aware that professionals in the field may have different opinions. Because of this and regular advances in medical research we strongly recommend that readers' independently verify specified treatments and drugs including manufacturers' guidance. Also, the categories do not indicate whether a particular treatment is generally appropriate or whether it is suitable for a particular individual. Ultimately it is the readers' responsibility to make their own professional judgements, so to appropriately advise and treat their patients.To the fullest extent permitted by law, BMJ Publishing Group Limited and its editors are not responsible for any losses, injury or damage caused to any person or property (including under contract, by negligence, products liability or otherwise) whether they be direct or indirect, special, incidental or consequential, resulting from the application of the information in this publication.</p></sec></notes></front></pmc><affiliations><list></list><tree><noCountry><name sortKey="Delaney, Geoff" sort="Delaney, Geoff" uniqKey="Delaney G" first="Geoff" last="Delaney">Geoff Delaney</name><name sortKey="Stebbing, Justin" sort="Stebbing, Justin" uniqKey="Stebbing J" first="Justin" last="Stebbing">Justin Stebbing</name><name sortKey="Thompson, Alistair" sort="Thompson, Alistair" uniqKey="Thompson A" first="Alistair" last="Thompson">Alistair Thompson</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003411 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 003411 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= PMC:2943780
|texte= Breast cancer (non-metastatic)
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:19450345" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |